Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KarXT + KarX-EC
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**KarXT + KarX-EC** is a combination therapy consisting of an immediate-release (IR) capsule formulation (KarXT) of xanomeline tartrate and trospium chloride, plus an enteric capsule of xanomeline (KarX-EC). Xanomeline is a selective muscarinic acetylcholine receptor agonist, and trospium chloride is a peripherally acting antimuscarinic agent used to mitigate peripheral cholinergic side effects of xanomeline. This combination is under investigation for the treatment of agitation and cognitive impairment associated with Alzheimer's disease, as well as in psychiatric disorders. The new dual-formulation is designed for both immediate and extended cholinergic activation profiles, aiming for improved efficacy and tolerability. Studies focus on long-term safety and efficacy in adult and adolescent populations with Alzheimer's-related agitation and other psychiatric conditions[4][7][8][9].
- Brand names
- Cobenfy
- Other names
- xanomeline tartrate/trospium chloride IR capsule + xanomeline enteric capsule
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)
Beyond the preview
Go deeper on KarXT + KarX-EC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KarXT + KarX-EC.